Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 APPLICATION POSITIONING GRID
2.2.5 COMPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 EPIDEMILOGY DATA
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMEWORK
8 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 ELISPOT KITS
8.2.1 BY ANALYTE
8.2.1.1. T CELL BASED KITS
8.2.1.1.1. HUMAN
8.2.1.1.2. MOUSE
8.2.1.1.3. RAT
8.2.1.1.4. PIG
8.2.1.1.5. OTHERS
8.2.1.2. B-CELL BASED KITS
8.2.1.2.1. HUMAN
8.2.1.2.2. MOUSE
8.2.1.2.3. OTHERS
8.2.2 BY UTILITY
8.2.2.1. DIAGNOSTIC KITS
8.2.2.2. RESEARCH KITS
8.2.3 BY TYPE
8.2.3.1. SINGLE ANALYTE ELISPOT KITS
8.2.3.2. DUAL-COLOR ELISPOT KITS
8.2.3.2.1. ]
8.2.4 BY PLATE TYPE
8.2.4.1. 96-WELL WHITE
8.2.4.2. 96-WELL STRIP
8.2.4.3. 384-WELL WHITE
8.2.5 BY AVAILIBILITY
8.2.5.1. REGULAR
8.2.5.2. PRECOATED
8.3 ELISPOT PLATFORM/ANALYZER
8.3.1 BENCH TOP
8.3.2 STANDALONE
9 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET, BY DISEASES
9.1 OVERVIEW
9.2 INFECTIOUS DISEASES
9.2.1 COVID-19
9.2.2 INFLUENZA
9.2.3 HIV
9.2.4 OTHERS
9.3 CANCER
9.4 AUTOIMMUNE DISEASES
9.5 TRANSPLANTATION
9.6 VACCINE DEVELOPMENT
9.7 ALLERGY
9.8 TH1/TH2, T CELL REGULATION
9.9 MONOCYTE AND DENDRITIC CELL ANALYSIS
9.1 OTHERS
10 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET, BY USAGE
10.1 OVERVIEW
10.2 CLINICAL APPLICATIONS
10.2.1 ELISPOT KITS
10.2.2 ELISPOT PLATFORM/ANALYZER
10.3 RESEARCH APPLICATIONS
10.3.1 ELISPOT KITS
11 ELISPOT PLATFORM/ANALYZER GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET , BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICAL LABORATORIES
11.2.1 ELISPOT KITS
11.2.2 ELISPOT PLATFORM/ANALYZER
11.3 RESEARCH AND ACADEMICS INSTITUTES
11.3.1 ELISPOT KITS
11.3.2 ELISPOT PLATFORM/ANALYZER
11.4 BIOPHARMACEUTICAL COMPANIES
11.4.1 ELISPOT KITS
11.4.2 ELISPOT PLATFORM/ANALYZER
11.5 DIAGNOSTIC LABS
11.5.1 ELISPOT KITS
11.5.2 ELISPOT PLATFORM/ANALYZER
11.6 CONTRACT RESEARCH ORGANISATION
11.7 OTHERS
12 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET , BY DISTRIBUTION
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET , COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3 COMPANY SHARE ANALYSIS: EUROPE
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13.5 MERGERS & ACQUISITIONS
13.6 NEW PRODUCT DEVELOPMENT & APPROVALS
13.7 EXPANSIONS
13.8 REGULATORY CHANGES
13.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET , BY GEOGRAPHY
14.1 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.1.1 NORTH AMERICA
14.1.1.1. U.S.
14.1.1.2. CANADA
14.1.1.3. MEXICO
14.1.2 EUROPE
14.1.2.1. GERMANY
14.1.2.2. FRANCE
14.1.2.3. U.K.
14.1.2.4. HUNGARY
14.1.2.5. LITHUANIA
14.1.2.6. AUSTRIA
14.1.2.7. IRELAND
14.1.2.8. NORWAY
14.1.2.9. POLAND
14.1.2.10. ITALY
14.1.2.11. SPAIN
14.1.2.12. RUSSIA
14.1.2.13. TURKEY
14.1.2.14. NETHERLANDS
14.1.2.15. SWITZERLAND
14.1.2.16. REST OF EUROPE
14.1.3 ASIA-PACIFIC
14.1.3.1. JAPAN
14.1.3.2. CHINA
14.1.3.3. SOUTH KOREA
14.1.3.4. INDIA
14.1.3.5. AUSTRALIA
14.1.3.6. SINGAPORE
14.1.3.7. THAILAND
14.1.3.8. MALAYSIA
14.1.3.9. INDONESIA
14.1.3.10. PHILIPPINES
14.1.3.11. VIETNAM
14.1.3.12. NEW ZEALAND
14.1.3.13. TAIWAN
14.1.3.14. REST OF ASIA-PACIFIC
14.1.4 SOUTH AMERICA
14.1.4.1. BRAZIL
14.1.4.2. ARGENTINA
14.1.4.3. REST OF SOUTH AMERICA
14.1.5 MIDDLE EAST AND AFRICA
14.1.5.1. SOUTH AFRICA
14.1.5.2. EGYPT
14.1.5.3. BAHRAIN
14.1.5.4. UNITED ARAB EMIRATES
14.1.5.5. KUWAIT
14.1.5.6. OMAN
14.1.5.7. QATAR
14.1.5.8. SAUDI ARABIA
14.1.5.9. REST OF MEA
14.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET , SWOT AND DBMR ANALYSIS
16 GLOBAL ENZYME LINKED IMMUNOSPOT ASSAYS MARKET , COMPANY PROFILE
16.1 BD
16.1.1 COMPANY OVERVIEW
16.1.2 REVENUE ANALYSIS
16.1.3 GEOGRAPHIC PRESENCE
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPEMENTS
16.2 THERMO FISHER SCIENTIFIC INC.
16.2.1 COMPANY OVERVIEW
16.2.2 REVENUE ANALYSIS
16.2.3 GEOGRAPHIC PRESENCE
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPEMENTS
16.3 CREATIVE BIOLABS
16.3.1 COMPANY OVERVIEW
16.3.2 REVENUE ANALYSIS
16.3.3 GEOGRAPHIC PRESENCE
16.3.4 PRODUCT PORTFOLIO
16.4 OXFORD IMMUNOTEC
16.4.1 COMPANY OVERVIEW
16.4.2 REVENUE ANALYSIS
16.4.3 GEOGRAPHIC PRESENCE
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPEMENTS
16.5 R&D SYSTEMS
16.5.1 COMPANY OVERVIEW
16.5.2 REVENUE ANALYSIS
16.5.3 GEOGRAPHIC PRESENCE
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPEMENTS
16.6 BIO-TECHNE
16.6.1 COMPANY OVERVIEW
16.6.2 REVENUE ANALYSIS
16.6.3 GEOGRAPHIC PRESENCE
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPEMENTS
16.7 MIKROGEN GMBH
16.7.1 COMPANY OVERVIEW
16.7.2 REVENUE ANALYSIS
16.7.3 GEOGRAPHIC PRESENCE
16.7.4 PRODUCT PORTFOLIO
16.7.5 RECENT DEVELOPEMENTS
16.8 RECENT DEVELOPEMENTS MERCK KGAA
16.8.1 COMPANY OVERVIEW
16.8.2 REVENUE ANALYSIS
16.8.3 GEOGRAPHIC PRESENCE
16.8.4 PRODUCT PORTFOLIO
16.8.5 RECENT DEVELOPEMENTS
16.9 U-CYTECH
16.9.1 COMPANY OVERVIEW
16.9.2 REVENUE ANALYSIS
16.9.3 GEOGRAPHIC PRESENCE
16.9.4 PRODUCT PORTFOLIO
16.9.5 RECENT DEVELOPEMENTS
16.1 CELLULAR TECHNOLOGY LIMITED
16.10.1 COMPANY OVERVIEW
16.10.2 REVENUE ANALYSIS
16.10.3 GEOGRAPHIC PRESENCE
16.10.4 PRODUCT PORTFOLIO
16.10.5 RECENT DEVELOPEMENTS
16.11 MABTECH
16.11.1 COMPANY OVERVIEW
16.11.2 REVENUE ANALYSIS
16.11.3 GEOGRAPHIC PRESENCE
16.11.4 PRODUCT PORTFOLIO
16.11.5 RECENT DEVELOPEMENTS
16.12 AGILENT TECHNOLOGIES
16.12.1 COMPANY OVERVIEW
16.12.2 REVENUE ANALYSIS
16.12.3 GEOGRAPHIC PRESENCE
16.12.4 PRODUCT PORTFOLIO
16.12.5 RECENT DEVELOPEMENTS
16.13 COVALAB, INC
16.13.1 COMPANY OVERVIEW
16.13.2 REVENUE ANALYSIS
16.13.3 GEOGRAPHIC PRESENCE
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPEMENTS
16.14 AUTOIMMUN DIAGNOSTIKA GMBH
16.14.1 COMPANY OVERVIEW
16.14.2 REVENUE ANALYSIS
16.14.3 GEOGRAPHIC PRESENCE
16.14.4 PRODUCT PORTFOLIO
16.14.5 RECENT DEVELOPEMENTS
16.15 DIACLONE SAS
16.15.1 COMPANY OVERVIEW
16.15.2 REVENUE ANALYSIS
16.15.3 GEOGRAPHIC PRESENCE
16.15.4 PRODUCT PORTFOLIO
16.15.5 RECENT DEVELOPEMENTS
16.16 ABCAM PLC
16.16.1 COMPANY OVERVIEW
16.16.2 REVENUE ANALYSIS
16.16.3 GEOGRAPHIC PRESENCE
16.16.4 PRODUCT PORTFOLIO
16.16.5 RECENT DEVELOPEMENTS
16.17 PROIMMUNE
16.17.1 COMPANY OVERVIEW
16.17.2 REVENUE ANALYSIS
16.17.3 GEOGRAPHIC PRESENCE
16.17.4 PRODUCT PORTFOLIO
16.17.5 RECENT DEVELOPEMENTS
16.18 ABNOVA CORPORATION
16.18.1 COMPANY OVERVIEW
16.18.2 REVENUE ANALYSIS
16.18.3 GEOGRAPHIC PRESENCE
16.18.4 PRODUCT PORTFOLIO
16.18.5 RECENT DEVELOPEMENTS
16.19 CREATIVE BIOLABS
16.19.1 COMPANY OVERVIEW
16.19.2 REVENUE ANALYSIS
16.19.3 GEOGRAPHIC PRESENCE
16.19.4 PRODUCT PORTFOLIO
16.19.5 RECENT DEVELOPEMENTS
16.2 BIORBYT LTD
16.20.1 COMPANY OVERVIEW
16.20.2 REVENUE ANALYSIS
16.20.3 GEOGRAPHIC PRESENCE
16.20.4 PRODUCT PORTFOLIO
16.20.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
17 RELATED REPORTS
18 CONCLUSION
19 QUESTIONNAIRE
20 ABOUT DATA BRIDGE MARKET RESEARCH
